cochinchinenin: isolated from Dracaena cochinchinensis; structure in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Dracaena | genus | A plant genus of the family Asparagaceae. The common name of dragon's blood is also used for CROTON and Daemonorops (ARECACEAE).[MeSH] | Asparagaceae | A family of flowering subshrubs and shrubs in the class Magnoliopsida.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 5315988 |
MeSH ID | M0451446 |
Synonym |
---|
cochinchinenin |
3-[2,4-dihydroxy-5-[3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)propyl]phenyl]-1-(4-hydroxyphenyl)propan-1-one |
AKOS016010171 |
400603-95-4 |
3-(2,4-dihydroxy-5-(3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)propyl)phenyl)-1-(4-hydroxyphenyl)propan-1-one |
DTXSID60415696 |
FT-0698379 |
3-(2,4-dihydroxy-5-(3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-propyl)phenyl)-1-(4-hydroxyphenyl)propan-1-one |
A873495 |
Excerpt | Relevance | Reference |
---|---|---|
" When the Hill's coefficients describing the dose-response relations of drugs were different, based on the concept of dose equivalence, the equations of additivity surfaces which can be applied to assess the interaction between three drugs were derived." | ( Material basis for inhibition of Dragon's Blood on evoked discharges of wide dynamic range neurons in spinal dorsal horn of rats. Chen, S; Guo, M; Liu, X, 2008) | 0.35 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |